Curative effect of type Ⅱ human recombinant of tumor necrosis factor receptor antibody fusion protein in the treatment of rheumatoid arthritis

赵浩, 赵福涛, 王艳玲. 不同剂量重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎疗效分析 [J]. 上海交通大学学报（医学版）, 2009, (12):1509-1511.

Raza K, Bu ckley C E, Salm onM. Treating very early rheumatoid arthritis [J]. Best Practice and Research:Clinical Rheumatology, 2006(5):849.

夏琳, 田东华, 季康. 来氟米特联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎疗效比较 [J]. 武警医学, 2012(4):349.doi: 10.3969/j.issn.1004-3594.2012.04.029.

Symm ons D P, S ilm an AJ. The world of biologies [J]. Lupus, 2006(3):122.

高洁生, 康志平, 彭文峰. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白计量递减联合改善病情的抗风湿药治疗外周型活动性强直性脊柱炎的临床评价 [J]. 中华风湿病学杂志, 2010(1):38.doi: 10.3760/cma.j.issn.1007-7480.2010.01.013.

尤欣, 唐福林. 类风湿关节炎临床和基础研究进展 [J]. 武警医学, 2010(3):185.doi: 10.3969/j.issn.1004-3594.2010.03.001.

Keystone E. Recent concepu in the inhibition of radiographicprogression with biologics [J]. Curt or'in Rheu-matol, 2009(3):231.

evicki D, Willian M K, Saurat J H. Impact of arthritis [J]. Annals of the Rheumatic Diseases, 2006(7):889.

和芳, 张虹, 李芹. 重组人Ⅱ型肿瘤坏死因子受体-Fc融合蛋白治疗类风湿关节炎疗效分析 [J]. 重庆医学, 2012, (27):2841.doi: 10.3969/j.issn.1671-8348.2012.27.019.

刘冬舟, 赵岩, 谭艳红. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对类风湿关节炎患者自身抗体的影响 [J]. 实用医学杂志, 2008, (15):2673.doi: 10.3969/j.issn.1006-5725.2008.15.060.

Haake H, Keneke J, Amann K. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis [J]. Med Klin(Munich), 2007, (10):852.

杨祖成, 王金帆, 张玉高. 益赛普联合甲氨蝶呤治疗类风湿关节炎的临床分析 [J]. 沪州医学院学报, 2013(2):164.

王笑青, 张永红, 王玉丽. 重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白减量疗法治疗强直性脊柱炎髋关节滑膜炎的疗效观察 [J]. 风湿病与关节炎, 2012(5):5.

Comby E, Tanaff P, Mariotte D. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy [J]. Journal of Rheumatology, 2006(1):24.

付文轶, 张宁. 重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白联合甲氨蝶吟对改善病情抗风湿药治疗无效活动性类风湿关节炎的疗效 [J]. 中华临床免疫和变态反应杂志, 2008(3):184.doi: 10.3969/j.issn.1673-8705.2008.03.004.

Main iRN, Breedveld F C. Su stained improvement over two years inphysical function, structural damage, and signs and symptoms among patients with rheumatoid arthrit is treated with infliximab and methotrexat [J]. Arth rit is Rheum, 2004(4):1051.